drugset / Trial / NCT01808131

Lesinurad and Allopurinol Combination Extension Study in Gout

NCT01808131

Phase 3 Completed 717 enrolled Ardea Biosciences, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will assess the serum uric acid lowering effects and safety of lesinurad in combination with allopurinol over a long-term timeframe.

Timeline

Start
2013-02
Primary completion
2016-08
Completion
2016-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Lesinurad Small molecule 200 mg
Subject Lesinurad Small molecule 400 mg

Indications